B
FULC icon

Bailard’s Fulcrum Therapeutics FULC Stock Holding History

Bailard’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,781
Closed -$90.4K – 796
2026
Q1 		$90.4K Hold
11,781
– – ﹤0.01% 728
2025
Q4 		$133K Sell
11,781
-15,100
-56% -$154K ﹤0.01% 729
2025
Q3 		$247K Hold
26,881
– – 0.01% 688
2025
Q2 		$185K Buy
+26,881
New +$144K ﹤0.01% 727
2025
Q1 		– Sell
-35,900
Closed -$169K – 775
2024
Q4 		$169K Buy
+35,900
New +$132K ﹤0.01% 700

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bailard's FULC Position: Q2 2026 in Review

Bailard sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 11,781 shares — an estimated $90.4K sold.

Bailard first reported a position in FULC in Q4 2024 and held it in 5 quarters. The position peaked at $247K in Q3 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Bailard reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bailard sold 11,781 Fulcrum Therapeutics shares in Q2 2026, an estimated $90.4K.
  • Bailard first reported a position in Fulcrum Therapeutics in Q4 2024 and held it in 5 quarters.
  • Bailard's Fulcrum Therapeutics position peaked at $247K in Q3 2025.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.